D
Danielle M. Brennan
Researcher at Cleveland Clinic
Publications - 91
Citations - 9235
Danielle M. Brennan is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Clopidogrel & Myocardial infarction. The author has an hindex of 38, co-authored 89 publications receiving 8306 citations. Previous affiliations of Danielle M. Brennan include Cleveland Clinic Lerner Research Institute.
Papers
More filters
Journal ArticleDOI
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Deepak L. Bhatt,Keith A.A. Fox,Werner Hacke,Peter B. Berger,Henry R. Black,William E. Boden,Patrice Cacoub,Eric A. Cohen,Mark A. Creager,J. Donald Easton,Marcus Flather,Steven M. Haffner,Christian W. Hamm,Graeme J. Hankey,S. Claiborne Johnston,Koon Hou Mak,Jean-Louis Mas,Gilles Montalescot,Thomas A. Pearson,P. Gabriel Steg,Steven R. Steinhubl,Michael A. Weber,Danielle M. Brennan,Liz Fabry-Ribaudo,Joan E. Booth,Eric J. Topol +25 more
TL;DR: In this article, the authors compared the effect of clopidogrel and low-dose aspirin on the rate of myocardial infarction, stroke, or death from cardiovascular causes.
Journal ArticleDOI
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls,Stephen J. Nicholls,Rishi Puri,Todd J. Anderson,Christie M. Ballantyne,Leslie Cho,John J.P. Kastelein,Wolfgang Koenig,Wolfgang Koenig,Ransi Somaratne,Helina Kassahun,Jingyuan Yang,Scott M. Wasserman,Rob Scott,Imre Ungi,Jakub Podolec,Antonius Oude Ophuis,Jan H. Cornel,Marilyn Borgman,Danielle M. Brennan,Steven E. Nissen +20 more
TL;DR: Among patients with angiographic coronary disease treated with statins, addition of evolocumab, compared with placebo, resulted in a greater decrease in PAV after 76 weeks of treatment, and further studies are needed to assess the effects of PCSK9 inhibition on clinical outcomes.
Journal ArticleDOI
Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity With Systemic Oxidative Stress and Cardiovascular Risk
Tamali Bhattacharyya,Stephen J. Nicholls,Eric J. Topol,Renliang Zhang,Xia Yang,David Schmitt,Xiaoming Fu,Mingyuan Shao,Danielle M. Brennan,Stephen G. Ellis,Marie Luise Brennan,Hooman Allayee,Aldons J. Lusis,Stanley L. Hazen +13 more
TL;DR: This study provides direct evidence for a mechanistic link between genetic determinants and activity of Pon1 with systemic oxidative stress and prospective cardiovascular risk, indicating a potential mechanism for the atheroprotective function of PON1.
Journal ArticleDOI
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial
Steven E. Nissen,Erik S.G. Stroes,Ricardo E Dent-Acosta,Robert S. Rosenson,Sam J. Lehman,Naveed Sattar,David Preiss,David Preiss,Eric Bruckert,Richard Ceska,Norman E. Lepor,Christie M. Ballantyne,Ioanna Gouni-Berthold,Mary Elliott,Danielle M. Brennan,Scott M. Wasserman,Ransi Somaratne,Rob Scott,Evan A. Stein +18 more
TL;DR: To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab, two-stage randomized clinical trial was conducted globally.
Journal ArticleDOI
Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial
Jacqueline Saw,Steven R. Steinhubl,Peter B. Berger,Dean J. Kereiakes,Victor L. Serebruany,Danielle M. Brennan,Eric J. Topol +6 more
TL;DR: Although ex vivo testing has suggested a potential negative interaction when coadministering a CYP3A4-metabolized statin with clopidogrel, this was not clinically observed statistically in a post hoc analysis of a placebo-controlled study.